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Psoriasis vulgaris is a skin disease potentially mediated Hence both CD8F and CD4F T cells are capable of
type 1 effector functions (TC1 and TH1, respectively).by pro-inflammatory cytokines produced by type 1
lesional T cells. The capability of individual T cells This activation scheme was repeated on peripheral
blood T cells from psoriatic patients versus healthyto produce these cytokines in lesional skin is not
known. In this study we measured the ability of controls, where we also found a type 1 bias. In
order to evaluate quantitatively the type 1 cytokinelesional and peripheral blood T cells to produce
intracellular interferon-g, tumor necrosis factor-a, bias, we compared the frequency of type 2 inter-
leukin-4 producing versus type 1 interferon-g pro-interleukin-2, interleukin-4, and interleukin-10 pro-
teins as detected by flow cytometric analysis. Cyto- ducing T cells in our assay and found a shift towards
type 1 producing cells. This shift reveals a type 1kine synthesis was induced by activation with
ionomycin/phorbol myristate acetate (in the presence differentiation bias in both lesional areas and in the
peripheral blood, which may indicate an imbalanceof Brefeldin A, which inhibits the exocytosis of these
cytokines). After stimulation, we found relatively within the T cell population, which is contributing
to the chronic or sustained immunologic activationhigh percentages of epidermal CD8 and CD4 T cells
capable of producing interferon-g, tumor necrosis of T cells found in this disease. Key words: interleukin-
4/interleukin-10/intracellular/ratio. J Invest Dermatolfactor-a, and interleukin-2, whereas few T cells,
< 11%, expressed interleukin-4 or interleukin-10. 113:752–759, 1999
P colony-stimulating factor (Grossman et al, 1989; Baker et al, 1991;Gomi et al, 1991; Uyemura et al, 1993; Vollmer et al, 1994; Olaniranet al, 1996) with a few reports of IL-10 and IL-5 (Olaniran et al,1996) in psoriatic lesions. As the majority of studies show littleIL-4, IL-5, or IL-10 message in lesional skin (Uyemura et al, 1993;soriasis vulgaris is a human inflammatory cell-mediatedautoimmune disorder (Uyemura et al, 1993; Gottliebet al, 1994, 1995; Bata-Csorgo et al, 1995a). Lesionalskin T cells are hypothesized to contribute pro-inflammatory/type 1 (T1) cytokines to initiate and/or
Schlaak et al, 1994; Asadullah et al, 1998), lesional T cells may notmaintain the cell-mediated keratinocyte hyperplasia in inflammatory
be able to produce these regulatory cytokines. Thus indicating thatlesions. Reverse transcription–polymerase chain reaction cytokine
specific type 2 (T2) cytokine producing cells are potentially absentprofiles of psoriatic skin reveal the potential production of many
from lesional skin. Although we realize that exceptions are foundpro-inflammatory cytokines such as interleukin (IL)-1 α , IL-
for IL-2, TNF-α, and IL-10, for ease of explanation in this study,1 β, IL-2, IL-6, IL-8, tumor necrosis factor (TNF)-α, TNF-β,
we will refer to T1 cells as those that produce IFN-γ, TNF-α, andtransforming growth factor-α and -β, and granulocyte/macrophage
IL-2 and T2 cells as those that produce IL-4 and IL-10 for reasons
which shall become apparent in this study.
In addition to studies showing the presence of T1 cytokine
Manuscript received December 18, 1998; revised July 15, 1999; accepted message in lesional skin, investigators have looked for protein
for publication July 22, 1999. expression, receptor expression, and signs of biologic activity of
Reprint requests to: Dr. Lisa M. Austin, Laboratory for Investigative the primary potential immunoregulatory cytokines IFN-γ and
Dermatology, Box 178, The Rockefeller University, 1230 York Avenue, New TNF-α. Whereas IFN-γ and its receptor has been shown to beYork, NY 10021-6399, U.S.A. Email: austinl@rockvax.rockefeller.edu relatively scarce in the epidermis by immunohistochemistry (LivdenAbbreviations: CTL, cytotoxic T lymphocyte; T1, type 1; T2, type 2.
et al, 1989; Nickoloff and Mitra, 1992) other cytokines such as1Austin LM, Ozawa M, Kikuchi T, Krueger JG: Intracellular TNF-α,
TNF-α (Nickoloff et al, 1991) and the TNFR1 (Nickoloff andIFN-γ, and IL-2 identify TC1 and TH1 effector populations in psoriasis
Mitra, 1992; Kristensen et al, 1993) are clearly present in thevulgaris plaque lymphocytes. Single-cell analysis by flow cytometry. J Invest
Dermatol 110:649, 1998 (abstr.) lesional epidermis. Biologic activity for both of these cytokines
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Biopsies At the time of blood collection, split-thickness skin biopsies
were taken from lesional areas of skin and processed for flow cytometry
as described (Austin et al, 1998). Briefly, the biopsies were rinsed twice in
phosphate-buffered saline containing Gentamicin (PBS-G) at 100 µg per
ml (Gibco-BRL, Gaithersburg, MD) and held at 4°C for 1 h before
processing. The biopsies were rinsed again and placed in 0.5% Dispase
(Sigma, St Louis, MO) for 12–15 h at 4°C, then rinsed in PBS-G and
trypsinized for 10–20 min at 37°C in trypsin/ethylenediamine tetra-
acetic acid 0.25 mg per ml (Clonetics, Walkersville, MD). The trypsin
was neutralized in RPMI containing 5% normal human serum (C-Six
Diagnostics, Mequon, WI), HEPES buffer (1 mM) (Gibco-BRL), and
gentamicin (0.5 µg per ml). After disassociating the tissue, large pieces
Figure 1. Cytokine expression related to differentiation status for were pulled away and the cells were pelleted at approximately 5003 g.
the two primary effector types of lymphocytes. This diagram shows Small, lymphocyte-sized live (Trypan blue-negative) epidermal cells were
the rationale for cytokine comparisons shown in this study (Del Prete, 1998). loaded on to 96-well plates at 5 3 104 to 1 3 105 cells or with blood
(PBMCs or ER1 fractions) at 1–2 3 105 cells in 100 ml of 5% normal
in the epidermis is suggested by the expression of ICAM-1, human serum and incubated approximately 5–8 h at 37°C. Typically,
HLA-DR, IL-8, and IP-10 on and in lesional keratinocytes 25,000–50,000 epidermal cells were analyzed with 1–8% of the cells live
CD31 T cells. Although CD3 is unaffected by trypsinization, the overnight(Gottlieb et al, 1988; Griffiths et al, 1989; Nickoloff et al, 1989;
incubation is necessary for recovery of both CD4 and CD8 expression.Barker et al, 1990; Paukkonen et al, 1992) as IFN-γ and TNF-α
We tested this procedure on control blood lymphocytes and found that Ttreatment of keratinocytes in vitro can upregulate the expression of
cells regain the original percentage of CD4 and CD8 T cells.these molecules (Barker et al, 1990; Groves et al, 1995).
IFN-γ and TNF-α coexpression is found in differentiated T1
Cytokine staining The skin cells and peripheral T cells were stainedeffector cytotoxic T lymphocyte (CTL) (Res et al, 1994) and
for cytokine production (Picker et al, 1995) and as described in the Bectondifferentiated CD4 T cells (Mosmann et al, 1986). Therefore, we
Dickinson technical bulletin (Becton Dickinson, Mansfield, MA) on theoutlined an identification scheme for T1 effectors (Fig 1) based on
FastImmune Cytokine System, based on Brefeldin A. Brefeldin A optimallystudies in mouse models and in vitro culture experiments with inhibits cytokine exocytosis of IL-2, IFN-γ, and TNF-α. Representative
human cells as published by other investigators (Prussin, 1997; Del levels of IL-4 and IL-10 can also be detected with this method [PharMingen
Prete, 1998). Although we did not expect to find many T2 cells, technical bulletin (PharMingen, San Diego, CA): I/C Cytokine Staining
we did look for them as some message for IL-4 and IL-10 had Protocol 5.19.1997]. This procedure was modified for smaller cell numbers
by activating and staining cells in 96-well plates, cell numbers as describedbeen reported in lesions. Immature or ‘‘naı¨ve’’ (T0) coexpress
above. The cells were activated with 1 µg per ml ionomycin (Calbiochem-IFN-γ and IL-4 whereas T1 versus T2 effector designations were
Novabiochem Corporation, San Diego, CA) and 25 ng PMA per ml;simply based on exclusionary IFN-γ or IL-4 expression, respectively.
unactivated cells were given an equal amount of stock solution vehicleTherefore, the goals of this study were: (i) to determine the
without the activation chemicals. Ten micrograms Brefeldin A per mloverall capability of lesional epidermal T cells and blood T cells
(Sigma) was added to both activated and unactivated samples. Ourfrom psoriasis vulgaris patients to produce five cytokines: IFN-γ, preliminary studies on lymphocyte cell lines showed that Brefeldin A alone
IL-4, TNF-α, IL-2, and IL-10, in relation to control blood T cells, did not induce cytokine production. After 5–7 h of activation, phenotypic
and (ii) to determine the capability of lesional epidermal CD8 and surface staining was accomplished by adding the antibodies directly to the
CD4 T cell subsets to produce IFN-γ, TNF-α, and IL-2. As no wells for 10–15 min, pelleting the cells by centrifuging at approximately
5003 g for 3–5 min, followed by one rinse with FACs wash (PBS, Ca-specific antigen has been clearly implicated in psoriasis, and as
and Mg-deficient, with 0.1% fetal bovine serum and 0.01% sodium azide).different superantigens stimulate cytokine production in specific
The cells were fixed for 10 min at room temperature in 200 µl of 1 3subsets which may or may not be directly involved with psoriatic
FACs LyzeBD, rinsed one time with 250 µl of FACs wash. The cells werelesions, we chose a global in vitro stimulation procedure with
incubated in 200 µl of 1 3 FACs PERMBD (mixed well) for 10 min ationomycin (the Ca21 ionophore A23187) in conjunction with the
room temperature, rinsed once with 250 µl of FACs wash, resuspended inphorbol ester 12-O-tetradecanoyl-phorbol 13-acetate (PMA). This 100 µl of FACs wash, then cytokine antibodies or isotype control antibodies
type of stimulation procedure, in the presence of inhibitors of were added for 30 min at room temperature. Following incubation in
cytokine exocytosis, Brefeldin A or monesin, is currently being cytokine antibodies, the cells were rinsed with 150 µl of FACs wash for
used in several laboratories to determine the capability of freshly the first rinse followed by one rinse with 250 µl of FACs wash. Cells were
resuspended in 1% formaldehyde in FACs wash and analyzed within 12 h.isolated human T cells to produce intracellular cytokines. Iono-
The samples were analyzed with three or four color staining using amycin/PMA stimulates the production of our five cytokines
FACSCalibur Flow Cytometer (Becton Dickinson) and CellQuest softwarewhereas Brefeldin A will inhibit their exocytosis from the cell thus
(Becton Dickinson). The percentage of cytokine staining was determinedallowing us to measure the capability of each cell to produce these
by subtracting control staining from test staining. In general, controlcytokines (Picker et al, 1995; Jason and Larned, 1997; Suni et al,
staining levels were established by setting quadrant markers with . 98%1998). The binding of anti-cytokine fluorochrome conjugated negative staining. When more than one sample from an individual
antibodies to permeabilized cells was analyzed by flow cytometry was stained for the same cytokine, sample values were averaged for
to reveal an overall potential for cytokine production and to that individual.
provide an insight into the differentiation status and the effector
function of T cells in psoriatic patients. Antibodies The antibodies used in this analysis were IL-2 fluorescein
isothiocyanate (FITC), IFN-γ FITC or phycoerythrin (PE), TNF-α PE,MATERIALS AND METHODS
IL-4 PE with isotype controls IgG1 FITC for the IL-2, IgG2a FITC, or
PE for the IFN-γ and platelet IgG1 PE (regular IgG1 PE with unboundPatients Eighteen adult patients with moderate-to-severe psoriasis
vulgaris (14 male, four female, ages 31–69, median age 40) were enrolled PE removed) for the IL-4 and TNF-α, Simultest IFN-γ FITC/IL-4
PE, Simultest Control IgG2a FITC/platelet IgG1 PE (all from Bectonin this study which was approved by the Rockefeller University Hospital
Institutional Review Board. Enrollment excluded patients with guttate, Dickinson). TNF-α with anti-trinitrophenol (TNP) mouse IgG1 isotype
control from PharMingen was used in the first three of 14 experiments aserythrodermic, or pustular psoriasis. With one exception, no arthritic
involvement was reported. There were two additional criteria for admission TNF-α was not yet available from Becton Dickinson. IL-10 and isotype
controls were from Caltag Labs (Burlingame, CA) except for two experi-to this study. First, they were untreated for a period of at least 1 mo prior
to their biopsy, and second . 10% of their body surface was covered with ments using PharMingen antibodies. The cells were stained either for 3 or
4 fluorochrome analysis. CD3 PerCP is used for three-color analysislesions. Control blood T cells were obtained from 10 people without a
personal history of skin disease (four male, six female, ages 21–65, median whereas CD3 APC was used for four-color analysis. The following
antibodies were used for phenotypic analysis: IgG1 FITC/PE/PerCP/APC,age 35) plus one control blood sample from an unknown person without
visible or hematologic evidence of disease, purchased from the New York CD3 PerCP/APC, CD4 PE/PerCP, CD8 PE/PerCP, and CD69 FITC
(Becton-Dickinson).Blood Center.
754 AUSTIN ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Data analysis Four types of comparisons were made. The first was a
peripheral blood lymphocyte analysis based on two groups: control,
nonpsoriatic healthy volunteers (n 5 11) and patients with moderate-to-
severe untreated psoriasis vulgaris (n 5 14). These groups were compared
with a Mann–Whitney U test. The second comparison of the T2/T1 ratios
(IL-4/IFN-γ) were done between the two groups of blood lymphocytes
(n 5 8 each) and then psoriatic blood lymphocytes were compared with
epidermal lymphocytes (n 5 6 each) with the Student’s t test. The third
comparison of psoriatic blood lymphocytes (n 5 14) to lesional epidermal
lymphocytes (n 5 8–11) were compared with the Mann–Whitney U test.
The fourth matched comparisons were done with the Student’s paired t
test for CD8 versus CD4 comparisons. CD81CD31 versus CD41CD31
information is based on direct CD81CD31 gating with direct CD41CD31
gating (control blood) or CD8–CD31 gating, from the epidermis. Signi-
ficance was considered at p ø 0.05 at the one-tail level.
RESULTS
Few peripheral blood T cells produce pro-inflammatory
cytokines unless stimulated with ionomycin/PMA The
single cell CD3 population was defined by combined gating based
upon gated APC CD31 or PerCP CD31 T cells and single viable
cells defined by forward scatter for cell size (FSC) versus side scatter
for cell granularity (SSC) identification. Cytokine synthesis within
individual T cells was determined by co-staining with FITC- and/
or PE-conjugated anti-cytokine antibodies. Figure 2(A) shows
isotype controls and Fig 2(B) the relative lack of T1 cytokine
production in unstimulated T cells treated with Brefeldin A. In
fact, few blood or lesional T cells produced detectable levels of
IFN-γ, TNF-α, or IL-2, whereas some IL-4 and IL-10 positive
cells were detected (Table I). As shown in Fig 2(C, D), in vitro
stimulation with ionomycin/PMA induced IFN-γ, TNF-α, or IL-
2 in a sizeable fraction of blood T cells from both controls and
psoriatic patients. The majority of T cells that produced IFN-γ
coexpressed high levels of TNF-α (Fig 2C, D, arrows), whereas
many cells that produced IL-2 also produced high levels of TNF-
α (not shown). The majority of cells producing IL-2 and IFN-γ
were in separate populations with low percentages of double-
positive cells (not shown).
Psoriatic blood T cells contain a larger population of IFN-g
and TNF-a producing cells than controls, after stimulation
with ionomycin/PMA T cell populations capable of producing
intracellular cytokines induced by ionomycin/PMA were evaluated
in blood T cells from 14 patients with untreated psoriasis vulgaris
and 11 controls. On average, these T cells showed similar expression
of combined intracellular and extracellular CD69 staining (Fig 3).
T cells from psoriatic patients contained, on average, a larger
population of cells producing each cytokine with the exception of
IL-4 (Fig 3). The inflammatory/effector cytokines IFN-γ (23% vs
Figure 2. In vitro ionomycin/PMA stimulation of T cells from both12%, p 5 0.03) and TNF-α (50% vs 36%, p 5 0.048) were
control and psoriatic blood T cells primarily induces IFN-g, TNF-a,found in significantly higher frequencies within the psoriatic T cell and IL-2. (A) Isotype control staining of stimulated control blood T cells.
populations. Although IL-2 expression was usually higher for the (B) Intracellular cytokine staining (in the presence of Brefeldin A), of
patient T cells, these approached statistical significance (p 5 0.09). freshly isolated normal control blood T cells (C) as compared with
The percentages of IL-41 T cells were similar between psoriatic stimulated control blood T cells stained with the same anti-cytokine
antibodies and (D) intracellular cytokine staining of stimulated psoriaticand control blood, although the percentages of IL-101 T cells
patient blood T cells. Isotype controls shown are typical for unactivatedappeared slightly higher, there was no significant difference between
and activated T cells. The arrow points to the majority of IFN-γ1 T cellsthe values.
which are in the TNF-αhi region for both psoriatic and control blood.
IL-4 and IFN-g ratios indicate a shift towards T1 differ-
entiation in psoriatic blood T cells One way to compare the
blood, total epidermal cell suspensions from psoriatic lesions werebalance of T1 versus T2 T cell differentiation is to calculate the
analyzed for cytokine expression. T cells were identified as describedratio between IL-4 and IFN-γ producing cells (IL-4/IFN-γ ratio)
above for blood samples by combined gating on both viable cells(Barna et al, 1994). As discrete populations of T cells synthesize
(SSC versus FSC) and CD31 cells (CD3 versus SSC) as shown inonly IL-4 or IFN-γ (Fig 4A), we calculated these ratios for
Fig 5(A). Isotype control levels for these CD31 lymphocytes wereperipheral blood T cells (Fig 4B). The mean of ratios in psoriatics
established for each anti-cytokine antibody (not shown) and withwas 0.15, significantly lower than the mean of 0.45 calculated for
unactivated cells as demonstrated for IFN-γ and TNF-α (Fig 5B),control T cells (p 5 0.007), indicating a definite shift of circulating
IL-2 (Fig 5C), IL-4 (Fig 5D), and IL-10 (Fig 5E). Please note thatT cells towards T1 cytokine production.
only CD31 T cells are plotted inFig 5(B–E). The overall percentages
of cytokine production were determined for psoriatic blood CD31Analysis of cytokine production by T cells isolated from
psoriatic lesions, after stimulation with ionomycin/ T cells and intraepidermal CD31 T cells isolated from untreated
psoriatic lesions (n 5 11) (Fig 6A). The major cytokines producedPMA With the stimulation andanalysismethodsused forperipheral
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Table I. Little T1 intracellular cytokine expression is
detected in unactivated cells incubated in Brefeldin A and
appropriate concentrations of vehicle but without
ionomycin and PMAa
Cytokine Normal control Psoriatic patient Patient
blood blood epidermis
IL-2 0.7% 6 0.5 (5) 0.3% 6 0.3 (14) 0.7% 6 0.5 (5)
IFN-γ 0.9% 6 0.7 (5) 0.4% 6 0.2 (14) 0.9% 6 0.7 (5)
TNF-α 1.5% 6 1.3 (5) 4.2% 6 4.0 (14) 1.5% 6 1.3 (5)
IL-4 2.3% 6 2.0 (3) 2.1% 6 1.0 (10) 5.1% 6 2.0 (3)
IL-10 18.9% 6 9.3 (4) 15.0% 6 5.5 (12) 15.0% 6 9.3 (4)
aMean 6 SEM (n).
Figure 3. Psoriatic patients’ peripheral blood T cells contain larger
populations of T1 cytokine producing cells. Cytokine expression in
activated peripheral blood cells between control (n 5 8–11) and psoriatic
patients (n 5 14). The psoriatic patients T cells have larger populations
producing IFN-γ (p 5 0.03) and TNF-α (p 5 0.048). The percentage of
CD691 T cells demonstrates the similar number of permeabilized T cells
expressing CD69 after stimulation with ionomycin/PMA in the presence
of Brefeldin A.
by intraepidermal T cells were TNF-α, IL-2, and IFN-γ with some T
cells producing IL-4 and very few cells producing IL-10. Population
means for the number of cells producing IFN-γ and TNF-α were
marginally higher for intraepidermal cells compared with blood cells
in the same group of patients whereas total numbers of CD691
T cells were similar between these groups. IL-4/IFN-γ ratios also
demonstrate a T1 shift in the epidermal T cells at 0.18, which is Figure 4. Patients’ T cells demonstrate a T1 differentiation shift
with lower IL-4/IFN-g ratios. (A) IFN-γ versus IL-4 populations incomparable with the ratio of 0.13 of matched patient blood values,
peripheral blood T cells of control volunteers and patients, a patient samplen 5 6 (Fig 6B). Overall, intraepidermal T cells show an even greater
is shown and (B) the psoriatic blood IL-4/IFN-γ ratio (n 5 14) is lowerbias towards T1 cytokine production than in psoriatic blood with
than the ratio found in normal blood (n 5 8) (p 5 0.007).the slightly larger IFN-γ and TNF-α populations and fewer IL-10
producing cells (13% vs 4%).
Comparison of potential for cytokine production between producing IFN-γ was much greater than in psoriatic blood or
control blood at 53% vs 11% vs 16% (respectively). Psoriatic bloodCD41 and CD81 T cell subsets in psoriatic lesions Using
four-color cytometric analysis, with APC CD3 to identify T cells CD8 and CD4 contained similarly sized TNF-α1 populations
(35% vs 37%) in contrast to control blood in which more CD8with PerCP CD4 or PerCP CD8 to subset these CD31 cells, we
studied the capability for ionomycin/PMA to induce cytokines make TNF-α than CD4 (34% vs 19%, p 5 0.001). High percentages
of both CD81 and CD41 T cells from the epidermis producedwithin these subsets from psoriatic skin lesions (n 5 3), psoriatic
blood (n 5 8), and control blood (n 5 11, not shown). The paired TNF-α (73% vs 59%, marginal significance at p 5 0.07). Again,
the overall percentage of these TNF-α producing cells was highert test for CD8/CD4 comparisons was used for information from
the same individual (Fig 7). We found that in both control blood in lesional epidermis than in blood, 73% vs 35% for CD8, and 59%
vs 37% for CD4. As expected, more CD41 T cells in psoriatic(16% vs 11%, p 5 0.001, not shown) and psoriatic blood (11% vs
5%, p 5 0.01), more CD81 T cells than CD41 T cells expressed blood produced IL-2 than CD81 T cells (23% vs 15%, p 5 0.04),
which we also found in control blood (23% vs 16%, p 5 0.02)IFN-γ. This bias was previously reported by others for control
blood (North et al, 1996; Jason and Larned, 1997). We also found (Prussin and Metcalfe, 1995; Jason and Larned, 1997). It was
surprising that more CD81 T cells in psoriatic lesions producedthat a much larger population of lesional intraepidermal CD81
T cells produced IFN-γ than CD4 (53% vs 23%, p 5 0.03). IL-2 compared with intraepidermal CD41 T cells (57% vs 45%,
marginal significance at p 5 0.06) as ionomycin/PMA stimulationComparatively, we found the population of intraepidermal CD8
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of control blood T cells induces statistically significant greater
numbers of CD4 T cells producing intracellular IL-2.
DISCUSSION
Autoimmune disorders and inflammatory reactions are currently
segregated into cell-mediated T1 or T2 categories (Mosmann and
Sad, 1996). These designations are primarily based on IFN-γ1
versus IL-41 amounts, respectively, as measured directly from tissue
or from tissue-derived clones for organ-specific disorders such as
rheumatoid arthritis (RA) (T1), multiple sclerosis (T1), and Grave’s
disease (T2). T2 designations can be confusing as there are two
ways in which T2 cells function. First, T2 cells are shown to
function in vitro to influence antibody responses. Secondly, they
are implicated but not proven to downregulate T1 responses
(D’Elios and Del Prete, 1998). Inflammatory skin diseases have also
been assigned effector type designations which are clearly aligned
with the detection of intracellular cytokine staining patterns. T1
cytokine production is found in cell-mediated inflammation as
shown with delayed-type hypersensitivity responses and in tubercu-
loid leprosy, whereas T2 cytokines are found in atopic dermatitis
and lepromatous leprosy. Within individual T cell subsets, both
CD4 (H) and CTL (C) contain T1 and T2 subsets designated TH1
and TH2 (Mosmann et al, 1986), TC1 and TC2 (Salgame et al,
1991), respectively.
Because psoriasis vulgaris lesions have shown a strong T1 bias
based on cytokine message, researchers sought to show that lesional
T cells produce these cytokines. And indeed, indirect evidence for
T1 cytokine producing cells in lesional skin was obtained from T
cell lines and clonal cell lines grown nonspecifically from psoriatic
skin biopsies. These lines were primarily CD41 with some CD81
lines, many secreting IFN-γ and TNF-α (Michel et al, 1987; Barna
et al, 1994; Prinz et al, 1994; Vollmer et al, 1994; Bata-Csorgo et al,
1995b; Jones et al, 1996) as measured either by reverse transcription–
polymerase chain reaction of the cells, or by enzyme-linked
immunosorbent assay from culture medium. To avoid bias of results
from clonal selection (Kelso and Groves, 1997), however, it is
more accurate to analyze T cells in or from psoriatic lesions before
clonal expansion. Recently, µ16% of T cells isolated directly from
psoriatic lesional epidermis were found to be capable of producing
IFN-γ after ionomycin/PMA stimulation (Szabo et al, 1998).
With the in vitro activation and intracellular cytokine staining
reported here, we found numerous lesional epidermal and bloodFigure 5. Lesional epidermal CD31 T cells express T1 cytokines
T cells with the capability to express T1 cytokines IFN-γ, TNF-α,when stimulated in vitro. (A) representative dot plots of epidermal cells
which show FSC (size) versus SSC (granularity) information in addition to and IL-2 whereas few cells express the T2 associated cytokines
CD31 staining compared with its isotype control. For the following dot IL-4 or IL-10. This type of cytokine profile parallels the relative
plots of CD31 T cells, the first column shows unactivated epidermal T kinds of cytokine expression by bulk mRNA measures as published
cells whereas the second column shows the in vitro activated epidermal T by these other investigators. Furthermore, we found it very
cells (B) IFN-γ and TNF-α, (C) IL-2, (D) IL-4, and (E) IL-10. interesting that a T1 differentiation bias could be detected in
peripheral blood T cells in these psoriatic patients when compared
with healthy controls. This finding is analogous to the recent report
Figure 6. The size of populations
expressing each cytokine is similar
between the epidermis and blood. (A)
The average size of the epidermal lesional
population producing each cytokine was
statistically similar (with marginal signific-
ances in some cases) to the peripheral blood
population (B) IL-4:IFN-γ ratios were
determined and also found to be similar
for blood and epidermal T cells for each
patient (n 5 6 for patient matched samples).
Although the majority of lesional epidermal
T cells express CD69 on variable numbers
of cells prior to ionomycin/PMA stimula-
tion, these values represent the total CD69
expression of permeabilized T cells show-
ing similar percentages between blood and
skin T cells after ionomycin/PMA treat-
ment in the presence of Brefeldin A.
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Roura-Mir et al, 1997; Schoendorf et al, 1997) or between clonal
lines induced to differentiate along either a T1 or T2 pathway
(Sunder-Plassmann et al, 1996). Similar measures of T1 differ-
entiation shifts were detected with intracellular staining, after in vitro
stimulation procedures, in T cells of other diseases such as RA
(Dolhain et al, 1996) Lyme arthritis (Gross et al, 1998), and Behc¸et’s
disease (Sugi-Ikai et al, 1998). In contrast, T2 shifts are observed
as expected in atopic dermatoses (Wierenga et al, 1990; Ferry et al,
1997; Nakazawa et al, 1997, 1998). In a comparison with published
information on RA synovial fluid cells, psoriatic epidermal T cells
contained larger numbers of differentiated T cells with a stronger
T1 bias than T cells in RA synovial fluid. Unlike RA synovial
fluid, we found few lesional epidermal cells expressing IL-4 or
IL-10, and virtually no T0 cells that coexpress IL-4 and IFN-γ
(Morita et al, 1998). Our results also suggest that T1 versus T2 T
cell frequencies can be altered when growing lymphocytes from
psoriatic lesions (Barna et al, 1994).
As expected, based on our earlier study where we showed that
Figure 7. Both CD81 and CD41 peripheral blood cells and a major portion of epidermal T cells were activated (CD251epidermal cells from psoriatic patients can produce IFN-g, TNF-
GMP-171) CTL (Austin et al, 1998) the majority of CD8 T cellsa, and IL-2 after stimulation with ionomycin/PMA. (A) IFN-γ
can produce IFN-γ and TNF-α as do many resident CD4 T cells.expression is consistently higher in the CD81 population when compared
Therefore, any T1 cytokine-mediated effector functions in lesionalwith the CD41 T cells in the epidermis (p 5 0.03), with a similar finding
in psoriatic blood (p 5 0.01) and normal blood (p 5 0.001, n 5 11, not epidermis would be contributed to by both CTL and CD4 T cells.
shown). (B) TNF-α expressing populations, whereas marginally significant As there usually are more CTL (.60%) in lesional epidermis than
(p 5 0.07) between the subsets, are greater in the epidermal CD8 CD4 (,40%), a phenomenon similar to synovial fluid in RA
population than in the patients’ peripheral blood (p 5 0.05). And, whereas (Morita et al, 1998), the CTL contribution towards the cytokine
there is still no difference between the subsets of TNF-α expressing cells contribution could be significant. Some of the epidermal T cells
in the psoriatic blood, in normal blood significantly more CD81 CD31 in our assay did not produce measurable amounts of cytokine.cells were expressing TNF-α than CD41 CD31 cells (p 5 0.001, n 511,
Many of these cells were CD41 T cells. There are severalnot shown). (C) Lesional CD81 CD31 populations were marginally larger
explanations for this including that these cells may not producethan CD41 CD31 cells (p 5 0.06) and were larger than IL-21 CD81
cytokine at levels high enough for cytometric detection due toCD31 populations in patient’s peripheral blood populations (p 50.04)
whereas in both sources of peripheral blood cells, psoriatic and normal, more their stage in the cell cycle, i.e., their effector contribution towards
CD41 T cells express IL-2 than CD8 T cells (p 5 0.04 and p 5 0.02, the lesional pathophysiology is finished in these established lesions.
respectively). Cells were gated for CD81CD31 whereas the CD41CD31 Alternatively they may represent nonfunctioning suppressor-like
information is based on both direct CD41CD31 gating (normal blood cells (Croft et al, 1994). The epidermal CD8 enrichment is unlike
and two each of the psoriatic epidermal and psoriatic blood samples) and the dermis which has the more typical CD4 (.60%)/CD8 (,40%)
indirect CD8–CD31 gating, depending on sample availability (normal ratio as found in blood, and thus epidermal effector cells mayvolunteers n 5 11, psoriatic blood n 5 6, psoriatic epidermis n 5 3).
provide a unique contribution to the psoriatic phenotype.
There is continuing controversy over the potential function of
the CD4 and CD8 lesional T cells in psoriasis. For example, it hasof a T2 bias found in peripheral blood T cells of patients with atopic
dermatitis using a similar type of ionomycin/PMA stimulation with been suggested that CD4 T cells are pathogenic effectors whereas
CD8 T cells function as suppressors (Bos and Rie, 1999). Theflow cytometric analysis (Sato et al, 1998). This T2 bias was found
in both CD4 and CD8 blood T cells, although atopic dermatitis predominance of T1 cytokine producing capability for both the
CD4 and CD8 subsets of epidermal T cells, suggests a role foris mainly considered a CD4-mediated skin disorder. Although
ionomycin/PMA bypasses antigen-specific activation pathways, and both T cell subsets as T1 effectors.
It is now evident that enhanced CTL effector function is inducedsome cells which may not have been actively producing cytokines
may become capable of doing so, the specificity for the cytokine by CD4 T cells which can be mediated through the dendritic cells
(Bhardwaj et al, 1994). Thus preactivated CD4 T cells providetype is maintained. As such, this method is useful in defining
cytokine producing potential (as indicating the overall extent of signals necessary for the ‘‘preconditioning’’ of the dendritic cells,
which in turn enhance CTL effector functions (Bennett et al, 1998;differentiation within the population) rather than the ongoing
production of cytokines by the individual cells in the inflamed Ridge et al, 1998; Schoenberger et al, 1998). Therefore, the CD4
T cell’s primary role in plaque formation may be to boost CTLtissue or in blood. Such capability would be better measured by
intracellular staining of T cells after antigen-specific stimulation cytokine effector function, as implied by the results in this study.
In addition, the potentially low numbers of psoriatic lesional T(Picker et al, 1995; Suni et al, 1998) as we found that the majority
of lesional and blood T cells did not produce measurable amounts cells capable of expressing IL-10 after ionomycin/PMA treatment
could allow the persistence of the psoriatic lesions (Abdullah et al,of intracellular pro-inflammatory cytokines without in vitro stimu-
lation. 1989) as mediated through antigen-presenting cells (Nestle et al,
1994; Mitra et al, 1995). Differentiation towards T1 T cells isWe were able to quantitate a T1 cytokine differentiation bias in
blood and lesional T cells with the use of IL-4/IFN-γ ratios. The influenced by the presence of bioactive IL-12 (Croft et al, 1994)
of which the bioactive form was recently found in the lesions ofIL-4/IFN-γ ratios of the control blood T cells were significantly
different than those from psoriatic blood T cells and emphasized psoriatic plaques (Yawalkar et al, 1998).
This study defines the cytokine potential of intralesional CD81the shift towards bulk T cell T1 cytokine production. And,
although, overall, fewer circulating blood T cells than epidermal T cells as pro-inflammatory with their ability to produce IFN-γ
and TNF-α. A similar CTL effector cell has been describedT cells expressed cytokines after ionomycin/PMA treatment, the
expression pattern within the populations was very similar to that (Guidotti et al, 1996), which had the ability to produce effector
cytokines without inflicting large-scale cellular death. This may beof T cells from the epidermis. Many investigators have used IFN-γ
versus IL-4 comparisons and ratios to measure the extent of the type of effector we find in psoriatic lesions. The exact nature
of the CTL contribution to the psoriatic phenotype, however, isdifferentiation within T cell populations in disease conditions,
between T cell lines from different types of diseases and from unknown. A cytolytic granule associated protein associated with
CTL activation, GMP-17, is found in vivo in psoriatic lesionalnormal individuals (Sunder-Plassmann et al, 1996; Guo et al, 1997;
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Ferry B, Antrobus P, Huzicka I, Farrell A, Lane A, Chapel H: Intracellular cytokineskin (Austin et al, 1998). We do not yet, however, know if
expression in whole blood preparations from normals and patients with atopicthese activated CTL are actually producing and secreting pro- dermatitis. Clin Exp Immunol 110:410–417, 1997
inflammatory cytokines within the lesion. Of the three T1 cytokines Fierlbeck G, Rassner G, Muller C: Psoriasis induced at the injection site recombinant
interferon gamma. Results immunohistologic Invests. Arch Dermatol 126:we assayed, IFN-γ and IL-2 are the two cytokines which could
351–355, 1990directly contribute to the induction of and worsening of the
Gomi T, Shiohara T, Munakata T, Imanishi K, Nagashima M: Interleukin 1alpha,plaques. Subcutaneous injections of IFN-γ have been shown to Tumor necrosis factor alpha and interferon gamma in psoriasis. Arch Dermatol
induce lesions in nonlesional areas of psoriatic patient’s skin and 127:827–830, 1991
worsen pre-existing psoriatic skin plaques (Fierlbeck et al, 1990). Gottlieb AB, Lifshitz B, Fu SM, Staiano-Coico L, Wang CY, Carter DM: Expression
of HLA-DR molecules by keratinocytes and presence of Langerhans cells inIf IL-2 is expressed in the lesion, it may function to support and
the dermal infiltrate of active psoriatic plaques. J Exp Med 164:1013–1028, 1986maintain lesional T cell activation via the numerous CD251 T
Gottlieb AB, Luster AD, Posnett DN, Carter DM: Detection of a gamma interferon-
cells found within the lesions (Krueger et al, 1995) as functional induced protein (IP-10) in psoriatic plaques. J Invest Dermatol 90:565, 1988
studies indicate in a mouse model for diabetes (von Herrath et al, Gottlieb S, Johnson R, Gilleaudeau P, Woodworth T, Nylen P, Gottlieb AB, Krueger
JG: A specific lymphocyte toxin (DAB389IL-2) reverses epidermal keratinocyte1995). Therefore, as the majority of intraepidermal lymphocytes in
activation in psoriasis: improvement correlates with elimination intraepidermalmany psoriatic patients are phenotypically acivated effector CTL
CD81 lymphocytes. J Invest Dermatol 102:531, 1994
(GMP-171CD81CD31) (Austin et al, 1998) and intraepidermal Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB,
CTL have the ability to produce effector cytokines (IFN-γ and Krueger JG: Response psoriasis to a lymphocyte-selective toxin (DAB389IL-2)
suggests a primary immune, but not keratinocyte, pathogenic basis. Nature MedTNF-α), these CTL are the primary candidate effector cells for
1:442–447, 1995cytokine mediation in this disease.
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